ClinicalTrials.gg
RecruitingNCT06650319WDUpdated Jan 23, 2026

A Clinical Study to Evaluate the Safety and Efficacy of LY-M003 Injection in Patients With Wilson Disease

An Early Phase 1 interventional study of LY-M003 in Wilson Disease, sponsored by Chaohui Yu. Recruiting at 1 site in China. Open to participants aged 10 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Chaohui Yu · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
10 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Hepatolenticular Degeneration with a site in China — 10 open to participants now, 11 under way, 1 of them phase 3. Hepatolenticular Degeneration · China.

Started
2024
with 2 others
Phase 1
3 of 15
2 open now
Primary completion
2026-12
later than 4 of 10 live
Registered
10th of 15
by date
Lead sponsor
1 of 15
Chaohui Yu

Among the 15 studies in Hepatolenticular Degeneration with a site in China, this one is one of 3 that started in 2024, is one of 3 in phase 1, reaches primary completion later than 4 of the 10 other live ones, and was the 10th registered.

Hepatolenticular Degeneration

80 studies on the registry are indexed under Hepatolenticular Degeneration; 31 are open to participants now.

Browse Hepatolenticular Degeneration studies →

Open to participants now

10 of the 15 studies in Hepatolenticular Degeneration with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 22 Hepatolenticular Degeneration studies recruiting now, 17 (77%) set no upper age limit and 4 (18%) stop at 75 or younger; 14 take children under 18; 3 take healthy volunteers.

This study: 10 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hepatolenticular Degeneration with a site in China, or all of them as a file.
02

Study summary

Wilson's disease (WD), also known as Wilson's disease, is a rare autosomal recessive metabolic disorder caused by a mutation of the copper transport ATPase β (ATP7B) gene located on the long arm of chromosome 13 (13q14.3). This leads to accumulation of copper ions in multiple organs such as liver, brain and kidney, resulting in organ involvement. In this study, LY-M003 Injection is a gene therapy products with rAAV8 vector. After a single intravenous infusion, LY-M003 can be transduced to the target organ of liver and express the ATP7B in hepatocytese.

Read the detailed description

This study adopts a prospective, single-center, open, single-arm, single-dose clinical design to evaluate the safety, tolerability, efficacy, immunogenicity, PD and PK characteristics of LY-M003 injection in WD patients, including the main study phase and the long-term follow-up study phase.

This study is designed with 4 dose groups and 2 cohorts (adult cohort and pediatric cohort), namely: Dose Group 1 (1.0 × 10¹³ vg/kg), Dose Group 2 (2.0 × 10¹³ vg/kg), Dose Group 3 (4.0 × 10¹³ vg/kg) and Dose Group 4 (6.0 × 10¹³ vg/kg). Among them, Dose Group 1 serves as the starting dose of this study. The decision to escalate to the 4th dose group shall be made by the investigators and collaborators based on the accumulated safety, efficacy and other relevant data. Based on the accumulated efficacy and safety data of enrolled adult subjects, the investigator and collaborators will determine the starting dose, subsequent enrollment doses, and the number of enrolled cases for pediatric subjects.

03

Conditions studied

  • Wilson Disease

Keywords

  • Gene therapy
04

Who can participate

Ages eligible
10 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject must be able to fully understood the purpose, nature, method, and possible adverse effects of the study, must be able to voluntarily participate in the study and voluntarily able to provide the written form (ICF).
  2. Patients diagnosed with Wilson Disease .
  3. Wilson Disease (WD) patients confirmed by laboratory tests to have biallelic mutations in the ATP7B gene.
  4. Subjects must be treatment-experienced to WD who have received standard treatment (eg, D-penicillamine or zinc acetate) for at least 6 months prior to the screening period.
  5. Subjects must restrict food with high copper content for at least 6 months prior to screening and continue this restriction during the entire duration of study participation.
  6. Subjects must be willing to refrain from donating blood, organs, tissues or cells during study participation.
  7. Negative pregnancy test in women of (WOCBP).
  8. Subjects and their partners who have no childbearing plans from the screening period to 6 months after the end of the study and are willing to adopt effective measures (e.g., abstinence, condoms, etc.); subjects have no plans to donate sperm or ova.

Exclusion criteria

Exclusion Criteria:

  1. AAV8 neutralizing antibody titer > 1:10 .
  2. Active gastrointestinal bleeding within the past 3 months.
  3. Decompensated cirrhosis or advanced hepatic disease, manifested as portal hypertension, ascites, splenomegaly, esophageal varices, hepatic encephalopathy, etc.
  4. Subjects with other liver diseases as determined by the investigator, such as immune hepatitis, alcoholic liver disease, primary biliary cholangitis, primary sclerosing cholangitis, and/or drug or toxic liver disease
  5. Subjects considered as complicated with severe hypersplenism and requiring splenectomy as judged by the investigator.
  6. Model for End-Stage Liver Disease (MELD) Score > 13.
  7. Other disorders of copper metabolism, such as chronic cholestatic liver diseases, disorders of glycosylation, copper metabolism disorders, etc.
  8. History of noncompliance with copper chelators or zinc agents within 6 months prior to screening, as determined by the investigator.
  9. Subjects with treatment-experienced WD who have and/or AST 5 times greater than the (ULN).
  10. Severe central nervous system symptoms urgent for intensive hospitalization judged by the investigator.
  11. \< 90 g/L.
  12. A history of epileptic seizures or other diseases that may potentially affect compliance with study procedures within 6 months prior to the screening period.
  13. surface antigen (HBsAg) positive, virus (HCV) antibody positive, (HIV) antibody positive or Treponema pallidum antibody positive.
  14. Subjects with end-stage renal disease receiving dialysis (chronic kidney disease stage 3 and above) or \< 60 mL/min.
  15. Severe hyperlipidemia (triglycerides > 1000 mg/dL).
  16. Subject received or plans to receive bone marrow transplantation, hematopoietic stem cell transplantation and/or major organ transplantation, including but not limited to liver transplantation, kidney transplantation, etc.
  17. Clinically diagnosed or judged as serious cardiovascular disease by the investigator (eg, classification of heart failure ≥ 3 according to [NYHA]).
  18. Patients with uncontrolled concomitant diseases or infectious diseases as judged by the investigator.
  19. Subjects who have to any component of LY-M003 injection.
  20. Subjects who have previously received gene therapy or cell therapy of any kind.
  21. Subjects who use systemic agents or receive therapy within 3 months prior to dosing (except for prophylactic immunosuppressive therapy as specified in protocol).
  22. Subjects with history of cancer within 5 years prior to screening, except for completely resected non-melanoma skin cancer, non- prostate cancer and completely cured ductal carcinoma in situ.
  23. Subjects who have vaccinated with attenuated within 4 months prior to screening or plan to receive a live attenuated vaccine during the clinical trial.
  24. Subjects who have received treatment or disposition with another drug or investigational device within 28 days or 5 half-lives (drug only), whichever is longer, prior to screening.
  25. Pregnant women (or women planning to become pregnant) or lactating women.
  26. Other circumstances in which the investigator deems the subject inappropriate for study participation.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    LY-M003 Dose group 1-Adult Cohort

    Adult participants receive a single, peripheral intravenous (IV) infusion of LY-M003 at dose group 1.

    Genetic: LY-M003

  • Experimental
    LY-M003 Dose group 2-Adult Cohort

    Adult participants receive a single, peripheral intravenous (IV) infusion of LY-M003 at dose group 2.

    Genetic: LY-M003

  • Experimental
    LY-M003 Dose group 3-Adult Cohort

    Adult participants receive a single, peripheral intravenous (IV) infusion of LY-M003 at dose group 3.

    Genetic: LY-M003

  • Experimental
    LY-M003 Dose group 4-Adult Cohort

    Adult participants receive a single, peripheral intravenous (IV) infusion of LY-M003 at dose group 4.

    Genetic: LY-M003

  • Experimental
    LY-M003-Pediatric Cohort

    Based on the accumulated efficacy and safety data of enrolled adult subjects, the investigator and collaborators will determine the starting dose, subsequent enrollment doses for pediatric participants.

    Genetic: LY-M003

Interventions

  • GeneticLY-M003

    A single peripheral intravenous (IV) infusion of LY-M003

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs) and serious adverse events (SAEs) within 52 weeks after the injection of LY-M003

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.

    Time frame: From enrollment to 52 weeks after administration

  2. Incidence of dose-limiting toxicity (DLT) events assessed within at least 28 days following LY-M003 infusion

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.The adverse events defined as dose-limiting toxicity (DLT) have been clearly specified in the protocol.

    Time frame: From enrollment to 52 weeks after administration

Secondary outcomes

  1. Percentage decrease in standard of care (SoC) medication use within 52 weeks after administration

    To assess the reduction in standard of care (SoC) medication use in subjects who completed administration of LY-M003 injection.

    Time frame: From enrollment to 52 weeks after administration

  2. Number and proportion of subjects who discontinue standard of care medication within 52 weeks after administration

    To evaluate the number and proportion of subjects who complete the administration of LY-M003 injection and discontinued standard of care (SOC) drugs.

    Time frame: From enrollment to 52 weeks after administration

  3. Change from baseline in serum ceruloplasmin content level through 52 weeks after administration

    To assess from baseline in serum ceruloplasmin content level through 52 weeks afterinjection of LY-M003.

    Time frame: From enrollment to 52 weeks after administration

  4. Change from baseline in total serum copper level through 52 weeks after administrationfrom

    To assess change from baseline in total serum copper level through 52 weeks after injection of LY-M003.

    Time frame: From enrollment to 52 weeks after administration

  5. Change from baseline in serum non-ceruloplasmin-bound copper (NCC) through 52 weeks after administration

    To assess change from baseline in serum non-ceruloplasmin-bound copper (NCC) through 52 weeks after injection of LY-M003.

    Time frame: From enrollment to 52 weeks after administration

  6. Change from baseline in 24-hour urinary copper Concentration through 52 weeks after administration

    To assess change from baseline in 24-hour urinary copper Concentration through 52 weeks after injection of LY-M003.

    Time frame: From enrollment to 52 weeks after administration

  7. Change from baseline in serum ceruloplasmin activity level through 52 weeks after administration

    To assess change from baseline in serum ceruloplasmin activity level through 52 weeks after injection of LY-M003.

    Time frame: From enrollment to 52 weeks after administration

  8. Assessment of the change from baseline in neurological subscale of the Unified Wilson Disease Rating Scale (UWDRS) through 52 weeks after administration.

    Assessment of the score change from baseline via the evaluation of neurological subscale of the Unified Wilson Disease Rating Scale (UWDRS).

    Time frame: From enrollment to 52 weeks after administration

  9. Assessment of the change from baseline in hepatic subscale of the Unified Wilson Disease Rating Scale (UWDRS) through 52 weeks after administration

    Assessment of the score change from baseline via the evaluation of hepatic subscale of the Unified Wilson Disease Rating Scale (UWDRS).

    Time frame: From enrollment to 52 weeks after administration

  10. Assessment of the change from baseline in psychiatric subscale of the Unified Wilson Disease Rating Scale (UWDRS) through 52 weeks after administration

    Assessment of the score change from baseline via the evaluation of psychiatric subscale of the Unified Wilson Disease Rating Scale (UWDRS).

    Time frame: From enrollment to 52 weeks after administration

  11. Change from baseline in liver elasticity through 52 weeks after administration

    Assessment of the change in liver elasticity from baseline in subjects via detection with hepatobiliary color Doppler ultrasound combined with ultrasound elastography.

    Time frame: From enrollment to 52 weeks after administration

  12. Change from baseline in Kayser-Fleischer (K-F) rings through 52 weeks after administration

    Evaluation of the change in Kayser-Fleischer (K-F) ring grade from baseline via slit-lamp examination of the eye.

    Time frame: From enrollment to 52 weeks after administration

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The study is in its early stages and will consider releasing data and related information when detailed and sufficient safety and efficacy data are available in subjects.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2024
First posted
Oct 21, 2024
StartActual
Sep 24, 2024
Primary completionEst.
Dec 30, 2026
CompletionEst.
Mar 30, 2030
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06650319
Lead sponsor
Chaohui Yu
Responsible party
Chaohui Yu (Chief physician, First Affiliated Hospital of Zhejiang University) — Sponsor-investigator
First posted
Oct 21, 2024
Start date
Sep 24, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Mar 30, 2030 (estimated)
Last update
Jan 23, 2026

Study contacts

Chaohui Yu, PhD
Contact
ych623@sina.com
86+13957161659
Yi Chen, PhD
Contact
yiiic@126.com
86+13735536389
Chaohui Yu, PhD
principal investigator · First Affiliated Hospital of Zhejiang University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion